Liver cancer, also known as hepatic cancer and primary hepatic cancer, is cancer that starts in the liver. Cancer which has spread from elsewhere to the liver, known as liver metastasis, is more common than that which starts in the liver. Symptoms of liver cancer may include a lump or pain in the right side below the rib cage, swelling of the abdomen, yellowish skin, easy bruising, weight loss, and weakness. The treatment of liver cancer patients is mainly determined by the organ involved, the tumor spread, the patient's general condition and age.
Market Analysis and Insights: Global Liver Cancer Therapeutics Market
The global Liver Cancer Therapeutics market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Liver Cancer Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Liver Cancer Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Liver Cancer Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Liver Cancer Therapeutics include ArQule, Bayer, Bristol-Myers Squibb, Celsion, Eisai, Exelixis, Roche, Merck and Pfizer, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Liver Cancer Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Liver Cancer Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Liver Cancer Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Liver Cancer Therapeutics revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Liver Cancer Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Liver Cancer Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including ArQule, Bayer, Bristol-Myers Squibb, Celsion, Eisai, Exelixis, Roche, Merck and Pfizer, etc.
By Company
ArQule
Bayer
Bristol-Myers Squibb
Celsion
Eisai
Exelixis
Roche
Merck
Pfizer
IntegraGen
Segment by Type
Targeted Therapy
Radiation Therapy
Immunotherapy
Chemotherapy
Other
Segment by Application
Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Liver Cancer Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liver Cancer Therapeutics companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Liver Cancer Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Liver Cancer Therapeutics Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Targeted Therapy
1.2.3 Radiation Therapy
1.2.4 Immunotherapy
1.2.5 Chemotherapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Liver Cancer Therapeutics Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hepatocellular Carcinoma
1.3.3 Cholangio Carcinoma
1.3.4 Hepatoblastoma
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liver Cancer Therapeutics Market Perspective (2018-2029)
2.2 Global Liver Cancer Therapeutics Growth Trends by Region
2.2.1 Liver Cancer Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Liver Cancer Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Liver Cancer Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Liver Cancer Therapeutics Market Dynamics
2.3.1 Liver Cancer Therapeutics Industry Trends
2.3.2 Liver Cancer Therapeutics Market Drivers
2.3.3 Liver Cancer Therapeutics Market Challenges
2.3.4 Liver Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Liver Cancer Therapeutics by Players
3.1.1 Global Liver Cancer Therapeutics Revenue by Players (2018-2023)
3.1.2 Global Liver Cancer Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Liver Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Liver Cancer Therapeutics, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Liver Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Liver Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liver Cancer Therapeutics Revenue in 2022
3.5 Global Key Players of Liver Cancer Therapeutics Head office and Area Served
3.6 Global Key Players of Liver Cancer Therapeutics, Product and Application
3.7 Global Key Players of Liver Cancer Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Liver Cancer Therapeutics Breakdown Data by Type
4.1 Global Liver Cancer Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Liver Cancer Therapeutics Forecasted Market Size by Type (2024-2029)
5 Liver Cancer Therapeutics Breakdown Data by Application
5.1 Global Liver Cancer Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Liver Cancer Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Liver Cancer Therapeutics Market Size (2018-2029)
6.2 North America Liver Cancer Therapeutics Market Size by Type
6.2.1 North America Liver Cancer Therapeutics Market Size by Type (2018-2023)
6.2.2 North America Liver Cancer Therapeutics Market Size by Type (2024-2029)
6.2.3 North America Liver Cancer Therapeutics Market Share by Type (2018-2029)
6.3 North America Liver Cancer Therapeutics Market Size by Application
6.3.1 North America Liver Cancer Therapeutics Market Size by Application (2018-2023)
6.3.2 North America Liver Cancer Therapeutics Market Size by Application (2024-2029)
6.3.3 North America Liver Cancer Therapeutics Market Share by Application (2018-2029)
6.4 North America Liver Cancer Therapeutics Market Size by Country
6.4.1 North America Liver Cancer Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Liver Cancer Therapeutics Market Size by Country (2018-2023)
6.4.3 North America Liver Cancer Therapeutics Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Liver Cancer Therapeutics Market Size (2018-2029)
7.2 Europe Liver Cancer Therapeutics Market Size by Type
7.2.1 Europe Liver Cancer Therapeutics Market Size by Type (2018-2023)
7.2.2 Europe Liver Cancer Therapeutics Market Size by Type (2024-2029)
7.2.3 Europe Liver Cancer Therapeutics Market Share by Type (2018-2029)
7.3 Europe Liver Cancer Therapeutics Market Size by Application
7.3.1 Europe Liver Cancer Therapeutics Market Size by Application (2018-2023)
7.3.2 Europe Liver Cancer Therapeutics Market Size by Application (2024-2029)
7.3.3 Europe Liver Cancer Therapeutics Market Share by Application (2018-2029)
7.4 Europe Liver Cancer Therapeutics Market Size by Country
7.4.1 Europe Liver Cancer Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Liver Cancer Therapeutics Market Size by Country (2018-2023)
7.4.3 Europe Liver Cancer Therapeutics Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Liver Cancer Therapeutics Market Size (2018-2029)
8.2 China Liver Cancer Therapeutics Market Size by Type
8.2.1 China Liver Cancer Therapeutics Market Size by Type (2018-2023)
8.2.2 China Liver Cancer Therapeutics Market Size by Type (2024-2029)
8.2.3 China Liver Cancer Therapeutics Market Share by Type (2018-2029)
8.3 China Liver Cancer Therapeutics Market Size by Application
8.3.1 China Liver Cancer Therapeutics Market Size by Application (2018-2023)
8.3.2 China Liver Cancer Therapeutics Market Size by Application (2024-2029)
8.3.3 China Liver Cancer Therapeutics Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Liver Cancer Therapeutics Market Size (2018-2029)
9.2 Asia Liver Cancer Therapeutics Market Size by Type
9.2.1 Asia Liver Cancer Therapeutics Market Size by Type (2018-2023)
9.2.2 Asia Liver Cancer Therapeutics Market Size by Type (2024-2029)
9.2.3 Asia Liver Cancer Therapeutics Market Share by Type (2018-2029)
9.3 Asia Liver Cancer Therapeutics Market Size by Application
9.3.1 Asia Liver Cancer Therapeutics Market Size by Application (2018-2023)
9.3.2 Asia Liver Cancer Therapeutics Market Size by Application (2024-2029)
9.3.3 Asia Liver Cancer Therapeutics Market Share by Application (2018-2029)
9.4 Asia Liver Cancer Therapeutics Market Size by Region
9.4.1 Asia Liver Cancer Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Liver Cancer Therapeutics Market Size by Region (2018-2023)
9.4.3 Asia Liver Cancer Therapeutics Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size by Type
10.2.1 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size by Application
10.3.1 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size by Country
10.4.1 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Liver Cancer Therapeutics Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 ArQule
11.1.1 ArQule Company Details
11.1.2 ArQule Business Overview
11.1.3 ArQule Liver Cancer Therapeutics Introduction
11.1.4 ArQule Revenue in Liver Cancer Therapeutics Business (2018-2023)
11.1.5 ArQule Recent Developments
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Liver Cancer Therapeutics Introduction
11.2.4 Bayer Revenue in Liver Cancer Therapeutics Business (2018-2023)
11.2.5 Bayer Recent Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Liver Cancer Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Revenue in Liver Cancer Therapeutics Business (2018-2023)
11.3.5 Bristol-Myers Squibb Recent Developments
11.4 Celsion
11.4.1 Celsion Company Details
11.4.2 Celsion Business Overview
11.4.3 Celsion Liver Cancer Therapeutics Introduction
11.4.4 Celsion Revenue in Liver Cancer Therapeutics Business (2018-2023)
11.4.5 Celsion Recent Developments
11.5 Eisai
11.5.1 Eisai Company Details
11.5.2 Eisai Business Overview
11.5.3 Eisai Liver Cancer Therapeutics Introduction
11.5.4 Eisai Revenue in Liver Cancer Therapeutics Business (2018-2023)
11.5.5 Eisai Recent Developments
11.6 Exelixis
11.6.1 Exelixis Company Details
11.6.2 Exelixis Business Overview
11.6.3 Exelixis Liver Cancer Therapeutics Introduction
11.6.4 Exelixis Revenue in Liver Cancer Therapeutics Business (2018-2023)
11.6.5 Exelixis Recent Developments
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Liver Cancer Therapeutics Introduction
11.7.4 Roche Revenue in Liver Cancer Therapeutics Business (2018-2023)
11.7.5 Roche Recent Developments
11.8 Merck
11.8.1 Merck Company Details
11.8.2 Merck Business Overview
11.8.3 Merck Liver Cancer Therapeutics Introduction
11.8.4 Merck Revenue in Liver Cancer Therapeutics Business (2018-2023)
11.8.5 Merck Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Liver Cancer Therapeutics Introduction
11.9.4 Pfizer Revenue in Liver Cancer Therapeutics Business (2018-2023)
11.9.5 Pfizer Recent Developments
11.10 IntegraGen
11.10.1 IntegraGen Company Details
11.10.2 IntegraGen Business Overview
11.10.3 IntegraGen Liver Cancer Therapeutics Introduction
11.10.4 IntegraGen Revenue in Liver Cancer Therapeutics Business (2018-2023)
11.10.5 IntegraGen Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
ArQule
Bayer
Bristol-Myers Squibb
Celsion
Eisai
Exelixis
Roche
Merck
Pfizer
IntegraGen
*If Applicable.